#GAIA PROJECT AUTONOMA PROFESSIONAL#

Overall uptake for both HBV and HCV testing was 75%. Over 11В months, 81,088 patients attended the ED 36,865 (45.5%) had a blood test.

Our model for contacting patients requiring linkage to care (new diagnoses/known but disengaged) evolved from initially primarily hospital-led to collaborating with regional health and community service networks. Reactive laboratory results were communicated directly to specialist clinical teams. We conducted a real-world service evaluation of a modified electronic patient record (EPR) system to include opportunistic opt-out HBV/reflex-HCV tests for any routine blood test orders for ED attendees aged в‰Ґ16В years. Universal HIV testing in our ED according to UK guidance has been operational since 2015. Routine blood-borne virus (BBV) testing in emergency departments (EDs) in high-prevalence areas is suggested by the European Centre for Disease Prevention and Control (ECDC) but there is limited evidence for this.

Innovative testing approaches and care pathways are required to meet global hepatitis B virus (HBV) and hepatitis C virus (HCV) elimination goals. Writing support was provided by Arthur Smyth-Medina (NexGen Healthcare Communications, UK) and funded by Gilead Sciences Ltd Initial data analyses were undertaken by BS (Basel Karo) and SB (Sooria Balasegaram) who are employees of HSA and received funding from Gilead Sciences Ltd. Content, conclusions and recommendations were agreed by consensus by all authors.

Clinical service delivery, data generation and analysis were done independently by NHS and HSA partners. Gilead provided technical expertise, project management and funding for hepatitis B virus and hepatitis C virus testing during the evaluation period, and support for care coordinator.

#GAIA PROJECT AUTONOMA PROFESSIONAL#

National Health Service (NHS) and Health Security Agency (HSA) partners contributed independent expertise and skills in their own professional capacity without additional financial support. This project was supported through an Association of the British Pharmaceutical Industry (APBI) joint working initiative with Gilead Sciences Ltd.

Gaia project autonoma